SCHEMBL20576364

SCHEMBL20576364

Clc1cc(-c2cc3ccccc3o2)nc(Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 6/20 0.51
▸ RAB9A P51151 6/20 0.51
▸ MAPT P10636 4/20 0.51
▸ METAP2 P50579 1/20 0.50
▸ GRM4 Q14833 1/20 0.49
▸ CYP19A1 P11511 1/20 0.46
▸ MKNK1 Q9BUB5 1/20 0.45
▸ MAOB P27338 4/20 0.44
▸ MAOA P21397 3/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ STAT1 P42224 1/20 0.43
▸ ADRA2A P08913 2/20 0.43
▸ F2RL3 Q96RI0 2/20 0.43
▸ KDM4E B2RXH2 4/20 0.42
▸ ALDH1A1 P00352 4/20 0.42
▸ HPGD P15428 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ ADRA2B P18089 1/20 0.42
▸ ADRA2C P18825 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792536 0.77 MKNK1 (0.48) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL21466185 0.77 CNR2 (0.53) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL103158 0.73 MAOB (0.63) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL30036439 0.73 MAOB (0.63) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL6534239 0.73 SIRT6 (0.53) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL21462312 0.72 MAOB (0.54) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL30332746 0.72 NPC1 (0.57) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL2149843 0.71 MAOB (0.61) NPC1RAB9AMAPTMETAP2GRM4
SCHEMBL3325699 0.70 ALDH1A1 (0.45) NPC1RAB9AMAPTKDM4EALDH1A1
SCHEMBL29478404 0.70 GRM4 (0.61) NPC1RAB9AMAPTMETAP2GRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3555095-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 — — EP disclosed
EP-3362451-B1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-04-12 — — EP disclosed
CN-110446711-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2022-02-15 — — CN disclosed
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-01-18 — — US disclosed
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-27 — — US disclosed
CN-109748915-B Inhibitors of influenza virus replication and methods of use and uses thereof 广东东阳光药业有限公司 2021-03-26 — — CN disclosed
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-23 — — US disclosed
CN-108276401-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2020-12-22 — — CN disclosed
US-20200339564-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-10-29 — — US disclosed
US-20200299294-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-09-24 — — US disclosed
US-10717732-B2 Inhibitors of influenza virus replication, application methods and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-07-21 — — US disclosed
CN-108218873-B Inhibitors of influenza virus replication and uses thereof 广东东阳光药业有限公司 2020-07-07 — — CN disclosed
US-20200085822-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-03-19 — — US disclosed
US-20180346463-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-12-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299294-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF POLRMT, EIF2AK2, POLM NPC1 2126/4885RAB9A 1791/4885MAPT 4252/4885
US-20180346463-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF POLRMT, EIF2AK2, POLM NPC1 2126/4885RAB9A 1791/4885MAPT 4252/4885
US-10927118-B2 Inhibitors of influenza virus replication and uses thereof EIF2AK2, POLRMT, ZC3HAV1 NPC1 2772/4885RAB9A 1263/4885MAPT 3563/4885
US-10717732-B2 Inhibitors of influenza virus replication, application methods and uses thereof POLRMT, EIF2AK2, POLM NPC1 2126/4885RAB9A 1791/4885MAPT 4252/4885
US-20200339564-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF EIF2AK2, ZC3HAV1, MAVS NPC1 2680/4885RAB9A 1232/4885MAPT 4019/4885
US-10987354-B2 Inhibitors of influenza virus replication and uses thereof ZC3HAV1, MAVS, POLRMT NPC1 2426/4885RAB9A 1304/4885MAPT 3480/4885
US-11225477-B2 Inhibitors of influenza virus replication, application methods and uses thereof POLRMT, EIF2AK2, POLM NPC1 2126/4885RAB9A 1791/4885MAPT 4252/4885
US-20200085822-A1 INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF ZC3HAV1, MAVS, POLRMT NPC1 2426/4885RAB9A 1304/4885MAPT 3480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback